2022 approvals show a shift in the development focus of anti-cancer antibody therapeutics towards China


ADCs have the potential to revolutionize the treatment of several cancers, but also autoimmune and infectious diseases, making them a significant
and promising class of therapies. Consequently, the US and EU approved
33 antibody therapeutics between 2016 and 2020, with most targeting
various tumors, while China only approved 10 during the same period.

In 2022, the number of ADCs approved in both regions was nearly the same as between 2016 and 2020, indicating the high growth potential of this form of therapy (Fig 1). However, in 2022 percentagewise the development focus of anti-cancer antibody therapeutics has shifted towards China, with around
67% of approvals for this disease in the region (Fig 2).
Since many years, the experienced project teams at abc biopply assist customers worldwide in the field of oncology drug discovery to advance
their development of antibody therapeutics faster and more cost-efficiently. For this purpose, the company offers a specially developed service package Quick Drug Efficacy Check.

The Quick Drug Efficacy Check Package delivers in the shortest time possible a most accurate ex vivo prediction of clinically relevant drug efficacy and
dosages during hit validation, lead optimization and the preclinical
test phase. It profits from the unique features of the 3D CoSeedis™
in chip technology forming physiologically relevant micro-tissues
in statistically significant quantities

Sources: www.antibodysociety.org , www.tandfonline.com and abc biopply in house data

Would you like to learn how you can speed up drug development
and make it more cost-effective?

Get in contact with us!


   Best regards

   Marco Leu, PhD
   abc biopply ag

   Direct Email / Phone +41 (0)79 834 95 56

Back to overview

Contact us